Navigation Links
TenX Biopharma Licenses Zanolimumab From Genmab

PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN).

Under the terms of the agreement, Genmab will receive an up-front license fee of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab.  TenX will be responsible for all future costs of developing, manufacturing and commercializing zanolimumab.  

"Zanolimumab has promise for treatment of patients with T cell cancers, and potential in other cancer types for which existing therapies are inadequate," said Gardiner F.H. Smith, Chief Executive Officer of TenX Biopharma. "We are building a pipeline of new medicines for high unmet need, with a focus on the patient through business efficiency."

Asher Nathan, Managing Partner of Zoticon Bioventures and the lead investor in TenX, said "TenX and zanolimumab represent the fourth late stage drug funding which we've led in the past two years.  I'm delighted that this important product will be available in the future, and look forward to the management team at TenX continuing to build value with novel cancer therapeutics."

"Genmab is pleased to find a partner who wishes to take zanolimumab forward in development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer.  "This is good news for patients who may one day benefit from treatment with zanolimumab."

About TenX

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.  For more information visit

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.  For more information visit

This press release contains forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. TenX does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Contact:  Gardiner F.H. Smith, Chief Executive Officer, TenX Biopharma

T: (304) 982-1240; E:

SOURCE TenX Biopharma, Inc.



SOURCE TenX Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... ScanWise Implant, the industry,s first MRI guided user interface ... scanning of patients with MR Conditional implants, such as ... the 2015 Radiological Society of North America Annual ... exams and supports diagnostic confidence of this growing patient ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... December 01, 2015 , ... ... Colon as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Until now, ... criteria set forth in the MOMS (Management of Myelomeningocele Study) trial. One of these ... Control and Prevention), a BMI of 18.5 to 24.9 is considered normal, 25 - ...
(Date:11/30/2015)... ... 2015 , ... Stress, anxiety, illness, infection or even a need for eyeglasses ... Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, ... tumors. , “Bad headaches that don’t go away, that don’t have any ...
Breaking Medicine News(10 mins):